Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate Fresenius Kabi and Formycon announced today that they have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara®* in Europe and Canada. The terms of the settlement are confidential. Log in or register to post comments
